IL93728A - Anti-VIH pharmaceutical preparations containing cyclic polyamines - Google Patents

Anti-VIH pharmaceutical preparations containing cyclic polyamines

Info

Publication number: IL93728A
Authority: IL; Israel
Prior art keywords: ring; hiv; composition according; compound; cyclic amine
Prior art date: 1989-03-17

Application number

IL9372890A

Other languages

English (en)

Hebrew (he)

Other versions

IL93728A0 (en

Original Assignee

Johnson Matthey Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-17

Filing date

1990-03-13

Publication date

1994-11-28

1990-03-13 Application filed by Johnson Matthey Plc filed Critical Johnson Matthey Plc

1990-12-23 Publication of IL93728A0 publication Critical patent/IL93728A0/xx

1994-11-28 Publication of IL93728A publication Critical patent/IL93728A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
230000036436 anti-hiv Effects 0.000 title claims description 4
125000004122 cyclic group Chemical group 0.000 title description 3
229920000768 polyamine Polymers 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 31
125000003277 amino group Chemical group 0.000 claims abstract 2
239000000203 mixture Substances 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 11
-1 cyclic amine Chemical class 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
239000002184 metal Substances 0.000 claims description 5
229910052751 metal Inorganic materials 0.000 claims description 5
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 3
CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
239000010839 body fluid Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000004185 ester group Chemical group 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
239000011248 coating agent Substances 0.000 claims description 2
238000000576 coating method Methods 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
241001430294 unidentified retrovirus Species 0.000 abstract description 2
238000000034 method Methods 0.000 description 7
230000000694 effects Effects 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
241000713340 Human immunodeficiency virus 2 Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 3
102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
239000010948 rhodium Substances 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
239000011701 zinc Substances 0.000 description 3
KUFDRRWNPNXBRF-UHFFFAOYSA-N 1,4,8,12-tetrazacyclopentadecane Chemical group C1CNCCCNCCNCCCNC1 KUFDRRWNPNXBRF-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
238000002513 implantation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229910052703 rhodium Inorganic materials 0.000 description 2
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
APCWGAGIRFNQOI-UHFFFAOYSA-N 1,2,3,4,5,6-hexazacyclooctadecane Chemical compound C1CCCCCCNNNNNNCCCCC1 APCWGAGIRFNQOI-UHFFFAOYSA-N 0.000 description 1
KDCBVVQAMMXRFB-UHFFFAOYSA-N 1,4,7,10,13-pentazacyclopentadecane Chemical compound C1CNCCNCCNCCNCCN1 KDCBVVQAMMXRFB-UHFFFAOYSA-N 0.000 description 1
CIKNXWYNBZBJHB-UHFFFAOYSA-N 1,4,8,13-tetrazacyclohexadecane Chemical compound C1CCNCCCNCCNCCCNC1 CIKNXWYNBZBJHB-UHFFFAOYSA-N 0.000 description 1
FVAXNVWNNZLAHK-UHFFFAOYSA-N 1,5,9,13-tetrazacycloheptadecane Chemical group C1CCNCCCNCCCNCCCNC1 FVAXNVWNNZLAHK-UHFFFAOYSA-N 0.000 description 1
YXPRJLINFVQPDT-UHFFFAOYSA-N 1,5,9,13-tetrazacyclohexadecane Chemical compound C1CNCCCNCCCNCCCNC1 YXPRJLINFVQPDT-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
XPVUWNNWLZFNKK-UHFFFAOYSA-N cu-cyclam Chemical compound C1CN2CCCN3CCN4[Cu]32N1CCC4 XPVUWNNWLZFNKK-UHFFFAOYSA-N 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

IL9372890A 1989-03-17 1990-03-13 Anti-VIH pharmaceutical preparations containing cyclic polyamines IL93728A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898906190A GB8906190D0 (en)	1989-03-17	1989-03-17	Improvements in chemical compounds

Publications (2)

Publication Number	Publication Date
IL93728A0 IL93728A0 (en)	1990-12-23
IL93728A true IL93728A (en)	1994-11-28

Family

ID=10653540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9372890A IL93728A (en)	1989-03-17	1990-03-13	Anti-VIH pharmaceutical preparations containing cyclic polyamines

Country Status (16)

Country	Link
EP (1)	EP0392666B1 (de)
JP (1)	JPH02279624A (de)
KR (1)	KR900013948A (de)
AT (1)	ATE108654T1 (de)
AU (1)	AU628492B2 (de)
CA (1)	CA2012150A1 (de)
DE (1)	DE69010736T2 (de)
ES (1)	ES2056374T3 (de)
GB (1)	GB8906190D0 (de)
HU (1)	HU206262B (de)
IE (1)	IE900936L (de)
IL (1)	IL93728A (de)
NO (1)	NO901231L (de)
NZ (1)	NZ232930A (de)
PT (1)	PT93477A (de)
ZA (1)	ZA901992B (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3888877A (en) *	1969-06-11	1975-06-10	Schering Corp	Macrocyclic compounds and complexes thereof
US4156683A (en) *	1973-03-26	1979-05-29	Schering Corporation	Complexes of macrocyclic compounds
EP0243352A1 (de) *	1985-10-21	1987-11-04	SERGIO, William	Verfahren zur ermässigung der wahrscheinlichkeit einer infektion durch aids-virus(htlv-iii/lav/arv)

1989
- 1989-03-17 GB GB898906190A patent/GB8906190D0/en active Pending
1990
- 1990-03-13 IL IL9372890A patent/IL93728A/en not_active IP Right Cessation
- 1990-03-14 HU HU901594A patent/HU206262B/hu not_active IP Right Cessation
- 1990-03-14 ES ES90302722T patent/ES2056374T3/es not_active Expired - Lifetime
- 1990-03-14 CA CA002012150A patent/CA2012150A1/en not_active Abandoned
- 1990-03-14 AT AT90302722T patent/ATE108654T1/de not_active IP Right Cessation
- 1990-03-14 EP EP90302722A patent/EP0392666B1/de not_active Expired - Lifetime
- 1990-03-14 DE DE69010736T patent/DE69010736T2/de not_active Expired - Fee Related
- 1990-03-15 NZ NZ232930A patent/NZ232930A/en unknown
- 1990-03-15 IE IE900936A patent/IE900936L/xx unknown
- 1990-03-15 ZA ZA901992A patent/ZA901992B/xx unknown
- 1990-03-16 AU AU51411/90A patent/AU628492B2/en not_active Ceased
- 1990-03-16 JP JP2064458A patent/JPH02279624A/ja active Pending
- 1990-03-16 NO NO90901231A patent/NO901231L/no unknown
- 1990-03-16 PT PT93477A patent/PT93477A/pt not_active Application Discontinuation
- 1990-03-17 KR KR1019900003615A patent/KR900013948A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
EP0392666B1 (de)	1994-07-20
ATE108654T1 (de)	1994-08-15
EP0392666A3 (de)	1993-03-03
GB8906190D0 (en)	1989-05-04
ES2056374T3 (es)	1994-10-01
KR900013948A (ko)	1990-10-22
PT93477A (pt)	1990-11-07
HU901594D0 (en)	1990-06-28
JPH02279624A (ja)	1990-11-15
HUT54300A (en)	1991-02-28
AU5141190A (en)	1990-09-20
IL93728A0 (en)	1990-12-23
DE69010736D1 (de)	1994-08-25
IE900936L (en)	1990-09-17
NO901231D0 (no)	1990-03-16
EP0392666A2 (de)	1990-10-17
CA2012150A1 (en)	1990-09-17
NZ232930A (en)	1992-05-26
ZA901992B (en)	1990-12-28
HU206262B (en)	1992-10-28
AU628492B2 (en)	1992-09-17
NO901231L (no)	1990-09-18
DE69010736T2 (de)	1994-11-24

Legal Events

Date	Code	Title	Description
1996-12-05	RH	Patent void

Publication	Publication Date	Title
CA2032261C (en)	2002-04-23	Antiviral polyheterocyclic dimers
US6001826A (en)	1999-12-14	Chemical compounds
EP0338515B1 (de)	1992-09-16	Verfahren zur Verhütung der AIDS-Übertragung durch Blutübertragung
NZ232929A (en)	1991-07-26	Tungsten compounds containing a lanthanide ion and their use in antiviral compositions
JPH0232093A (ja)	1990-02-01	抗レトロウィルスジフルオロ化ヌクレオシド類
US5026726A (en)	1991-06-25	Gossylic iminolactones and gossylic lactones and their anti-viral activities
JPH06505728A (ja)	1994-06-30	長鎖の抗ウィルス化合物
IL93728A (en)	1994-11-28	Anti-VIH pharmaceutical preparations containing cyclic polyamines
ES2148234T3 (es)	2000-10-16	Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
EP1652525A1 (de)	2006-05-03	Anti-coronavirus-arzneimittel
PT97609A (pt)	1992-02-28	Processo para a preparacao de uma composicao farmaceutica para o tratamento de celulas infectadas com o virus da imunodeficiencia humana e dispositivo ou artigo tratado com essa composicao
US4971977A (en)	1990-11-20	Anti-viral pharmaceutical compositions
WO1992003052A1 (en)	1992-03-05	Method for suppression of hiv replication by ascorbate for chronic and acute hiv infection
WO1992009292A1 (en)	1992-06-11	Improvements in chemical compounds
CA1307740C (en)	1992-09-22	Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus
KR100532542B1 (ko)	2005-12-01	아르세닉산, 메타아르세나이트 또는 이들의 약제학적허용가능한 염을 함유한 에이즈 예방 및 치료용 약제 조성물
JPH03227925A (ja)	1991-10-08	エイズ原因ウィルスに対する抗ウイルス剤
JPH05117143A (ja)	1993-05-14	抗ウイルス剤
WO2022028839A1 (en)	2022-02-10	Domperidone for use as antiviral agent
JPS63253026A (ja)	1988-10-20	エイズ・ウイルス増殖抑制剤
JPH05105626A (ja)	1993-04-27	抗ウイルス剤
EP0320271A2 (de)	1989-06-14	Dimethylsulfoxid und Analoga als antiretrovirale Agenzien